+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Pharmaceutical Grade, Food Grade), By Application (Pharmaceutical Manufacturing, Food and Health Products, Other applications including cosmetics and research), By End User (Contract Manufacturing Organizations (CMOs), Nutraceutical & Supplement Brands, Pharmaceutical Companies), By Primary Material (Hypromellose (HPMC), Pullulan, Starch), By Capsule Size (Size 0 and Size 00, Size 1, 2 and 3, Size 4 and 5), and Regional Forecast, 2026-2034
The global empty vegetarian capsules market was valued at USD 1.47 billion in 2025 and is estimated at USD 1.58 billion in 2026. The market is projected to reach USD 2.83 billion by 2034, representing a 7.6% CAGR during 2026–2034.
Empty vegetarian capsules are two-piece oral dosage shells produced mainly from hypromellose (HPMC), pullulan, or starch-derived materials. They serve pharmaceutical, nutraceutical, dietary-supplement, clinical-development, and specialty formulation uses where manufacturers seek non-animal shells, low-moisture options, label flexibility, or differentiated dissolution profiles.
The market is moving beyond simple substitution for gelatin. Suppliers are broadening plant-based capsule portfolios for immediate release, delayed release, liquid fill, dry-powder inhalation, moisture-sensitive formulations, and titanium-dioxide-free appearance systems. This increases value per capsule in applications where shell performance is directly linked to formulation stability, branding, or regulatory requirements.
Growth is supported by large-scale supplement consumption and the continuing use of oral solid dosage forms across pharmaceuticals. The commercial constraint is cost and qualification: switching shell materials can require formulation testing, stability work, supplier validation, and line optimization, so adoption tends to be fastest where consumer positioning or technical performance creates a clear economic return.
Source: CDC/NCHS dietary-supplement use; USP hard hypromellose capsule-shell monograph; ACG U.S. capsule investment.
The study covers empty plant-based two-piece capsule shells supplied for pharmaceutical, nutraceutical and related oral-delivery applications, with analysis by grade, application, end user, primary material, capsule size and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Year | 2034 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Pharmaceutical Grade; Food Grade |
| By Application | Pharmaceutical Manufacturing; Food and Health Products; Other applications including cosmetics and research |
| By End User | Contract Manufacturing Organizations (CMOs); Nutraceutical & Supplement Brands; Pharmaceutical Companies |
| By Primary Material | Hypromellose (HPMC); Pullulan; Starch |
| By Capsule Size | Size 0 and Size 00; Size 1, 2 and 3; Size 4 and 5 |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Lonza Group AG; CapsCanada; Natural Capsules Limited; Dah Feng Capsule; ACG World; K-CAPS; Farmacapsulas SA; Fortcaps Healthcare Ltd.; BioCaps; GFR Pharma; SMPNutra; SD Head; PIM Ventures (Healthcaps); Qingdao Yiqing Biotech Co., Ltd. |
The market includes empty hard vegetarian capsule shells sold to manufacturers, contract organizations, brands, laboratories and other professional users. HPMC, pullulan and starch-based shells are included when supplied as empty capsule components for downstream filling.
Finished medicines, finished dietary supplements, capsule-filling machinery, active pharmaceutical ingredients and softgel finished products are outside the core revenue boundary unless discussed as downstream demand indicators.
Vegetarian capsule adoption is supported by pharmaceutical and supplement manufacturers seeking vegan, halal, kosher, non-animal or clean-label presentation. Product certification and transparent composition increasingly influence procurement for global brands that serve multiple consumer groups.
HPMC shells offer lower moisture content than conventional gelatin and are widely positioned for hygroscopic or moisture-sensitive fills. Pullulan is used in premium applications where oxygen-barrier performance and natural-origin positioning are valuable. These technical differences allow suppliers to compete on performance rather than price alone.
USP now defines hard hypromellose capsule shells as a recognized compendial article, while FDA maintains hypromellose entries across approved oral dosage forms in its inactive-ingredient resources. Clearer standards support supplier qualification and formulation transfer into regulated applications.
Switching from gelatin to vegetarian shells can require stability studies, dissolution work, line adjustments, sourcing qualification and documentation updates. For high-volume commodity formulations, these costs can preserve gelatin use unless the alternative shell solves a technical problem or supports a premium market position.
ACG's planned U.S. hard-shell capsule facility and ongoing regional expansions by manufacturers reflect customer demand for shorter lead times, dual sourcing and reduced geographic concentration. Supply resilience is increasingly part of supplier selection for pharmaceutical and nutraceutical customers.
Sources: USP-NF; U.S. FDA Inactive Ingredients Database; ACG; Lonza/Capsugel; Natural Capsules corporate disclosures.
Suppliers now offer dedicated HPMC products for immediate release, delayed release, liquid filling and dry-powder inhalation rather than a single generic vegetarian shell. This supports premiumization and makes capsule material part of formulation design.
Capsule suppliers are expanding titanium-dioxide-free and naturally opacified options as pharmaceutical and supplement brands reassess colorants, visual identity and consumer expectations. Capsugel introduced Vcaps Plus White Opal HPMC capsules using calcium carbonate for a semi-opaque white appearance in 2025.
ACG announced a USD 200 million U.S. hard-shell capsule program, with an initial Atlanta facility and a second expansion phase. Local output can reduce lead times and strengthen supply continuity for North American customers.
Natural Capsules reported firm HPMC orders and expected its HPMC business to support FY26 growth and profitability. This illustrates how plant-based shells are becoming a strategic margin pool rather than a niche product line.
Capsule technology is being positioned for increasingly complex formulations, including moisture-sensitive fills, delayed release and emerging oral biologic or peptide concepts. Successful commercialization can expand demand beyond conventional supplement and generic-drug use.
USP defines hard hypromellose capsule shells as HPMC-and-water two-piece shells that may also contain approved functional additives. The material's established compendial identity and broad supplier base make HPMC the most commercially important vegetarian capsule platform.
Pullulan capsules compete through natural-origin positioning and oxygen-barrier properties. Their higher input cost limits commodity use, but they are attractive for premium nutraceuticals and sensitive fills where product protection supports higher pricing.
Sizes 0 and 00 remain central because they balance fill capacity and swallowability for a wide range of pharmaceutical and supplement doses. Smaller sizes support lower-dose and specialty products, helping suppliers serve clinical, pediatric and high-potency applications.
By grade, the market is divided into pharmaceutical-grade and food-grade vegetarian capsules. Grade selection determines documentation, testing, consistency requirements and customer qualification intensity.
Pharmaceutical-grade capsules hold the leading commercial position because regulated drug products require tighter controls for identity, dimensions, microbiology, dissolution and supplier documentation. Long qualification cycles also favor established suppliers with consistent global manufacturing standards.
Food-grade capsules are closely linked to dietary supplements, functional ingredients and wellness brands. Growth is supported by vegan positioning, clean-label marketing, e-commerce product launches and demand for alternatives to animal-derived gelatin.
Application demand is led by pharmaceutical manufacturing, followed by food and health products and smaller specialty uses.
Pharmaceutical manufacturing represents the most demanding application because shell performance affects filling efficiency, dissolution, stability and regulatory submissions. HPMC is particularly relevant for formulations sensitive to moisture or cross-linking risk.
Nutraceutical and supplement brands use vegetarian capsules to align delivery format with vegan, allergen-conscious, halal, kosher and clean-label positioning. The channel also supports faster product refresh cycles and broader color or printing customization.
Research, cosmetics and specialty formulation work create smaller but technically diverse demand. These applications often value small batches, unusual sizes, custom colors or specialized release profiles more than commodity scale.
End-user demand spans pharmaceutical companies, nutraceutical and supplement brands, and contract manufacturing organizations that fill products for multiple customers.
Pharmaceutical companies prioritize validated suppliers, lot consistency, documentation, regulatory support and global continuity. Their qualification burden favors long-term supplier relationships and supports premium service models.
Supplement brands drive rapid adoption of plant-based shells because capsule material itself is visible in product claims and consumer positioning. Smaller brands can also access specialized vegetarian formats through contract manufacturers.
CMOs concentrate demand across multiple customers and formulations. Their need for flexible capsule compatibility, broad size availability and reliable replenishment makes them influential in supplier selection and new-material adoption.
HPMC, pullulan and starch provide different balances of cost, moisture performance, oxygen protection, processing behavior and label positioning.
HPMC is the leading material because it combines broad regulatory familiarity, strong film-forming properties, low moisture and compatibility with multiple pharmaceutical and nutraceutical fills. Supplier innovation now extends HPMC into delayed-release, liquid-fill and inhalation formats.
Pullulan is positioned for premium clean-label and oxygen-sensitive products. Its natural fermentation origin and barrier performance support differentiation, although higher material costs make adoption more selective.
Starch-based shells serve selected food-grade and specialty applications where plant origin and cost balance are important. Their market role is narrower because HPMC has deeper pharmaceutical acceptance and a broader supplier ecosystem.
Capsule size influences fill weight, patient experience, equipment settings and formulation flexibility. Standard sizes dominate production while smaller formats serve lower-dose and specialized products.
Sizes 0 and 00 are widely used across pharmaceuticals and supplements because they accommodate common dose volumes while remaining compatible with high-speed filling equipment. Their installed production base supports the largest recurring shell demand.
Mid-to-small sizes support lower-dose products, pediatric or consumer-friendly formats and formulations with high active potency. They are important for portfolio breadth even when unit volumes are lower than sizes 0 and 00.
The smallest standard sizes are used where precise low fill weights, clinical development or high-potency ingredients require compact shells. They command a specialized role rather than broad mass-market volume.
Regional performance is shaped by treatment access, manufacturing concentration, supplement or drug utilization, reimbursement, regulatory requirements, and the maturity of distribution channels. The analysis emphasizes commercially material regional differences rather than forcing unsupported country market shares.
North America leads due to mature pharmaceutical and supplement industries, high consumer familiarity with dietary supplements, broad retail and e-commerce channels, and significant capsule-supplier presence. New local manufacturing investment is also improving supply resilience.
CDC/NCHS reported 57.6% of adults aged 20 years and older had used a dietary supplement in the prior 30 days in 2017–2018. That large recurring supplement base supports demand for differentiated capsule formats, while ACG's planned Atlanta facility adds domestic hard-shell capacity.
Source: CDC/NCHS; ACG
Europe remains a substantial market for pharmaceutical-grade and premium nutraceutical capsules. Demand is shaped by strong quality requirements, plant-based consumer preferences, and the need to qualify materials across multiple national markets.
Asia-Pacific combines major capsule manufacturing centers with expanding domestic pharmaceutical and nutraceutical consumption. China and India are central to regional production, while Japan and Australia support higher-value regulated and premium wellness applications.
Demand is supported by local pharmaceutical production, imported premium capsules and growth in health-product retail. Supplier economics are strongly influenced by price sensitivity, distributor reach and the ability to provide regulatory documentation in local markets.
Halal positioning, pharmaceutical localization and expanding supplement channels support selective growth, especially in GCC markets and South Africa. Market development remains uneven because manufacturing scale and purchasing power vary widely across countries.
The USP hard hypromellose capsule-shell monograph establishes defined composition and quality expectations for HPMC shells. Compendial recognition supports specification development and cross-company qualification for regulated products.
Vegetarian, vegan, halal, kosher, non-GMO and allergen-related certifications are commercially important where capsule composition is part of the brand promise. Suppliers increasingly maintain multiple certification pathways to simplify multinational launches.
Pharmaceutical and large nutraceutical buyers increasingly evaluate backup capacity, geographic diversification, change-control discipline and lead-time reliability alongside price. This favors manufacturers able to operate multi-site networks or support regional inventory.
Competition is shaped by product performance, regulatory compliance, manufacturing or commercialization scale, distribution reach, price discipline, portfolio breadth, and the ability to respond to changing clinical or consumer preferences. The public overview focuses on market structure rather than reproducing company-by-company paid data.
Lonza/Capsugel and ACG offer broad capsule platforms spanning standard HPMC, specialty release profiles and customized appearance options. Their global regulatory support and technical services make them strong partners for complex or multinational programs.
Natural Capsules, Dah Feng Capsule, Healthcaps and other regional producers compete through local manufacturing, shorter lead times, targeted certifications and pricing. Expansion into HPMC enables these companies to participate in higher-value categories.
ACG's U.S. investment increases regional competition, while Lonza's planned divestiture of Capsules & Health Ingredients creates potential ownership change around one of the industry's largest capsule platforms. Customers are likely to monitor continuity, investment and service levels closely.
Supplier competition is increasingly centered on delayed release, liquid filling, low-moisture performance, TiO2-free opacity, natural color systems and specialized capsule geometry rather than standard shell supply alone.
The investment includes dedicated gelatin and vegetarian HPMC capsule manufacturing in Atlanta, Georgia. The initial facility is intended to shorten lead times and strengthen North American supply resilience, with operations targeted for early 2027.
Source: ACG
The new vegan, TiO2-free HPMC capsule uses calcium carbonate as an opacifier, illustrating supplier investment in alternative appearance systems and clean-label product design for health and nutrition applications.
Source: Capsugel
The company stated that HPMC capsules were expected to support FY26 topline and profitability, with firm orders providing visibility for expansion of its U.S.-focused HPMC business.
Source: Natural Capsules
Lonza's 2025 annual-report materials state that an agreement was signed to divest the CHI business, with closing expected in the second half of 2026. The transaction is strategically relevant because CHI includes the Capsugel capsule franchise.
Source: Lonza
The empty vegetarian capsules market is forecast to expand from USD 1.58 billion in 2026 to USD 2.83 billion by 2034. Growth is expected to come from broader HPMC adoption, premium nutraceutical formats, regional capacity investment, and application-specific capsule technology.
| Forecast Theme | 2026–2034 Direction |
|---|---|
| HPMC penetration | Expected to remain the principal value-growth engine as pharmaceutical and nutraceutical users expand plant-based, low-moisture and application-specific capsule use. |
| Premium formats | Pullulan, delayed-release HPMC, liquid-fill systems and specialized appearance solutions should grow faster than basic commodity shells where they solve a technical or brand-positioning need. |
| Regional supply | North American and Asian capacity additions are likely to reduce lead times and broaden dual-sourcing options, increasing competition for multinational customers. |
| Value versus volume | Unit volume can rise faster than revenue in high-competition standard capsules, while premium materials and specialized formats support higher realization. |
| Supplier differentiation | Technical support, regulatory documentation, certifications, change control and continuity of supply will remain as important as shell price in regulated applications. |
2025 base year, 2026 estimate, 2034 forecast and 2026–2034 CAGR.
Commercial positioning across every segmentation dimension retained in the syndicated study.
Five-region assessment with selective country signals where authoritative evidence materially improves interpretation.
Market structure, principal companies, strategic positioning and competitive pressure points.
Demand drivers, constraints, pricing or access factors, and structural market forces.
Material choice, compendial standards, certifications, dissolution, moisture behavior and application-specific shell technologies.
The empty vegetarian capsules market assessment combines top-down market reconciliation with bottom-up analysis of product availability, treatment or consumption patterns, manufacturer positioning, regional access, and channel structure. Historical market anchors are normalized to the fixed 2025 base year, 2026 estimated year and 2034 forecast framework used throughout this report overview.
Secondary research prioritizes regulators, government agencies, pharmacopeial standards, clinical and professional bodies, peer-reviewed literature, company filings, official investor communications, product labels, and other primary sources. Exact external statistics are used selectively when they clarify demand, regulation, adoption, access, or competition.
Market boundaries separate empty capsule-shell revenue from finished drug or supplement revenue. Supplier capacity, product portfolios, certifications, dosage-form standards and end-user demand indicators are used to test whether segment positioning and regional direction remain commercially coherent.
The global market was valued at USD 1.47 billion in 2025, is estimated at USD 1.58 billion in 2026, and is projected to reach USD 2.83 billion by 2034, representing a 7.6% CAGR during 2026–2034.
Hypromellose (HPMC) is the leading material because of its broad pharmaceutical acceptance, low-moisture properties, versatile formulation compatibility and established global supplier base.
Pharmaceutical manufacturing is the leading application, while food and health products are a high-growth demand source linked to plant-based and clean-label supplement positioning.
North America is the largest regional market, supported by mature pharmaceutical and supplement industries, high supplement consumption and significant supplier presence.
HPMC capsules combine plant-based positioning with low moisture, broad formulation compatibility, regulatory familiarity and expanding options for delayed release, liquid fill and specialty applications.
Key companies include Lonza/Capsugel, ACG World, Natural Capsules, Dah Feng Capsule, K-CAPS, Farmacapsulas, Healthcaps and other regional specialists.
The forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
